Abstract

Timeline

15th October 2026

Abstract Submission
Opens

1st March 2027

Abstract
Submission Closes

24th March 2027

Abstract
Acceptance Notification

31st March 2027

Registration and Payment Deadline for Accepted Abstracts

1
Abstract submission is open to both local and international delegates.
2
All abstracts submitted must be in English.
3
Once an abstract is selected, at least one of the authors of the abstract MUST register for the conference. Payment for conference registration should reach the Conference Secretariat before 31^st March 2027 to ensure that your abstracts will be published in the e-abstract book.
4
The abstract title should not exceed 120 characters.
5
The abstract should not exceed 300 words.
6
Abstracts submitted must follow the abstract submission guidelines, instructions and required information as stated. The NOSC 2027 Scientific Committee reserves the rights to disqualify the abstract if any needs are not met.
7
Encore abstracts will not be accepted. Encore abstract is a re-submission of an original abstract with minor changes in line with conference guidelines.

**Encore abstract is a paper where the research is done by another party and has a doctor to put their name as the author of the abstract.

Please read the instructions carefully, as abstracts submitted not according to these instructions will not be accepted.
Abstracts can only be submitted electronically through the abstract submission link. Abstract sent by post, fax or email WILL NOT BE ACCEPTED. Delegates may submit more than ONE abstract (please use the same email address).
Clinical track: encompasses research directly related to the assessment, diagnosis, treatment, complications and clinical outcomes of people living with obesity, while Para-clinical track: encompasses behavioural, nutritional, psychosocial, public health, implementation, health-system and societal research relevant to obesity prevention and care.
Authors may select their preferred track at the time of abstract submission. However, the Scientific Committee reserves the right to reassign abstracts to the most appropriate track following review, based on the primary focus and content of the research.
Track allocation is based on the nature of the research and not the professional background of the submitting author.

Only submissions received by 1^st March 2027 will be eligible for Best Oral or Best Poster prizes.
Your abstract will be published in the e-abstract/e-programme book as submitted. Please ensure you check your data carefully before submitting.
Please contact the Conference Secretariat at secretariatmyos@gmail.com should you need any assistance.
All submitted abstracts will undergo a peer-review process by a panel of expert reviewers. Accepted abstracts will be selected for either oral or poster presentations. The NOSC 2027 Scientific Committee reserves the right to re-categorise any accepted abstract.
Authors will be notified of the method of presentation, which will be decided by the NOSC 2027 Scientific Committee.
Abstract submitters will be informed of the status of their abstracts once the reviewing process is completed.
Judges’ decisions are final. No appeal will be entertained.

1
Abstract title:
- The title is limited to 120 characters excluding spaces and should be brief and relevant.
- Special characters should NOT be used in your title but spelt out instead (e.g. α should be written as alpha, β as beta).
- Only use standard abbreviations and generic drug names in the title. Capitalise each word in the title.
2
Abstract body:
- Structure: The abstract should have the following sub-headings: - Introduction, Methods, Results, and Conclusion.
- Layout: Please fill in according to the sections provided. Do not include graphs, tables or illustrations in the abstract.
- Word count: The abstract is limited to 300 words.
- Only commonly accepted abbreviations should be used (e.g. OGTT, IGT, ACEI). Less widely recognized abbreviations may be used if introduced on first usage (e.g. ambulatory blood pressure monitoring, ABPM).
- Only approved and generic (non-proprietary) drug names should be used.
- Do NOT enter the title, authors, or grant information into the abstract body submission field.
3
Please ensure that your abstract does not contain spelling, grammatical or scientific errors, as it will be published in the e-abstract/e-programme book exactly as submitted.